Samuel David, MD
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,145 of the $1,792 with a category attached, or 63.9%. Boston Scientific accounts for 61.1% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2019 at $1,135 and has fallen 90.3% since, to $110 in 2024. That places this record below the midpoint for urology clinicians in NE, where the typical reported total is $2,774.
Across 42 payments — averaging $42.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$1K
- Endo Pharmaceuticals Inc.$188
- Dendreon Pharmaceuticals LLC$164
- Johnson & Johnson$99
- Astellas Pharma US Inc$89
- KARL Storz Endoscopy-america$51
- plus $107 from 5 others
What the payments were for
- Travel & lodging$64636%
- Food & beverage$1,14564%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 17 | $1,094 |
| Endo Pharmaceuticals Inc. | 5 | $188 |
| Dendreon Pharmaceuticals LLC | 3 | $164 |
| Johnson & Johnson | 5 | $99 |
| Astellas Pharma US Inc | 5 | $89 |
| KARL Storz Endoscopy-america | 1 | $51 |
| Neotract Inc. | 2 | $48 |
| Therapeuticsmd, Inc. | 1 | $17 |
| Conmed Corporation | 1 | $15 |
| Metuchen Pharmaceuticals | 1 | $13 |
| Ferring Pharmaceuticals Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AMS$646
- AdVance XP$149
- PROVENGE$131
- XIAFLEX$125
How this compares
$1,792 in reported general payments places this provider in the 40th percentile of 79 urology providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tamsulosin Hcl | 105 | $1,630 |
| Solifenacin Succinate | 24 | $726 |
| Finasteride | 49 | $404 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 15 | $347 |
| Oxybutynin Chloride ErOxybutynin Chloride | 13 | $166 |
Paid to pharmacies, not to this prescriber.
Other urology in Omaha
- John BishayOmaha$138K
- Rebecca McCreryOmaha$71K
- Judson DaviesOmaha$67K
- Stefanie BolteOmaha$59K
- Michael FeloneyOmaha$29K
- Andrew TrainerOmaha$12K
- Stephen LeslieOmaha$12K
- Jon MortonOmaha$11K
- Brett HillOmaha$11K
- John HorganOmaha$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.